Pharmacogenetic CYP2D6 variability, phenoconversion and treatment outcomes: A Danish population-based cohort study in 6,798 individuals initiating atomoxetine treatment

Introduction Atomoxetine, a first-line treatment option for ADHD, is affected by pharmacogenetic (PGx) variation of the drug-metabolizing enzyme CYP2D6. Despite the recommendation of CYP2D6 testing, the use of PGx-guided dosing remains low in Denmark. Objectives We investigated wide-ranging clinic...

Descrizione completa

Dettagli Bibliografici

Autori principali:	K. Ishtiak-Ahmed, C. Lunenburg, J. Thirstrup, L. Clausen, P. Thomsen, C. Gasse
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Cambridge University Press 2022-06-01
Serie:	European Psychiatry
Soggetti:	treatment switching CYP2D6 inhibitors adhd sleeping problem
Accesso online:	https://www.cambridge.org/core/product/identifier/S0924933822005880/type/journal_article
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!